Changes in peritoneal membrane permeability and proteinuria in patients on peritoneal dialysis after treatment with paricalcitol - a preliminary study

Clinical Nephrology

Volumn 78, Issue 2, 2012, Pages 93-99

  Coronel, Francisco ^a   Cigarran, Secundino ^b   Gomis, Antonio ^a   Rodríguez Cubillo, Beatriz ^a   Herrero, José Antonio ^a   Delgado, Pablo ^a   Delgado, Jesus ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b HOSPITAL DA COSTA   (Spain)

Author keywords

Hyperparathyroidism; Paricalcitol; Peritoneal dialysis; Peritoneal membrane; Proteinuria; Vitamin D

Indexed keywords

PARICALCITOL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROL GROUP; CREATININE BLOOD LEVEL; DIALYSATE; DRUG EFFICACY; FEMALE; HUMAN; HYPERPARATHYROIDISM; INFLAMMATION; MALE; MEMBRANE PERMEABILITY; PERITONEAL DIALYSIS; PERITONEUM; PLASMA; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ULTRAFILTRATION;

ERGOCALCIFEROLS; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PERITONEUM; PERMEABILITY; PROSPECTIVE STUDIES; PROTEINURIA;

EID: 84865078194     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107570     Document Type: Article

References (40)

1. Goffin E. Peritoneal membrane structural and functional changes during peritoneal dialysis. Semin Dial. 2008; 21: 258-265.
2. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD; The Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993; 329: 1456-1462.
3. Coronel F, Cigarrán S, García-Mena M, Herrero JA, Calvo N, Pérez-Flores I. [Irbesartan in hypertensive non-diabetic advanced chronic kidney disease. Comparative study with ACEI]. Nefrologia. 2008; 28: 56-60. PubMed.
4. Praga M, Andrade CF, Luño J, Arias M, Poveda R, Mora J, Prat MV, Rivera F, Galceran JM, Ara JM, Aguirre R, Bernis C, Marín R, Campistol JM. Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial. Nephrol Dial Transplant. 2003; 18: 1806-1813.
5. Coronel F, Hortal L, Naranjo P, Cruceyra A, Barrientos A. Captopril, proteinuria and peritoneal protein leakage in diabetic patients. Nephron. 1989; 51: 443.
6. Duman S, Günal AI, Sen S, Asçi G, Ozkahya M, Terzioglu E, Akçiçek F, Atabay G. Does enalapril prevent peritoneal fibrosis induced by hypertonic (3.86%) peritoneal dialysis solution? Perit Dial Int. 2001; 21: 219-224. PubMed.
7. Coronel F, Berni A, Cigarrán S, Calvo N, Herrero JA. Effects of angiotensin II receptor blocker (irbesartan) on peritoneal membrane functions. Adv Perit Dial. 2004; 20: 27-30.
8. Kolesnyk I, Dekker FW, Noordzij M, Le Cessie S, Struijk DG, Krediet RT. Impact of ACE inhibitors and AII receptor blockers on peritoneal membrane transport characteristics in long-term peritoneal dialysis patients. Perit Dial Int. 2007; 27: 446-453.
9. Nessim SJ, Perl J, Bargman JM. The renin-angiotensin-aldosterone system in peritoneal dialysis: is what is good for the kidney also good for the peritoneum? Kidney Int. 2010; 78: 23-28.
10. Helming L, Böse J, Ehrchen J, Schiebe S, Frahm T, Geffers R, Probst-Kepper M, Balling R, Lengeling A. 1alpha,25-Dihydroxyvitamin D3 is a potent suppressor of interferon gamma-mediated macrophage activation. Blood. 2005; 106: 4351-4358.
11. Mizobuchi M, Nakamura H, Tokumoto M, Finch J, Morrissey J, Liapis H, Slatopolsky E. Myocardial effects of VDR activators in renal failure. J Steroid Biochem Mol Biol. 2010; 121: 188-192.
12. Li YC. Vitamin D regulation of the renin-angiotensin system. J Cell Biochem. 2003; 88: 327-331.
13. Freundlich M, Quiroz Y, Zhang Z, Zhang Y, Bravo Y, Weisinger JR, Li YC, Rodriguez-Iturbe B. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int. 2008; 74: 1394-1402.
14. Martin KJ, González EA, Gellens M, Hamm LL, Abboud H, Lindberg J. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol. 1998; 9: 1427-1432. PubMed.
15. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003; 63: 1483-1490.
16. Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, Fadem S, Levine B, Williams L, Andress DL, Sprague SM. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis. 2006; 47: 263-276.
17. Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, Williams L, Batlle D. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 2005; 68: 2823-2828.
18. Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z, Light RP, Agarwal R. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension. 2008; 52: 249-255.
19. Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis. 2009; 54: 647-652.
20. Davies SJ, Bryan J, Phillips L, Russell GI. Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant. 1996; 11: 498-506.
21. Chung SH, Heimbürger O, Stenvinkel P, Bergström J, Lindholm B. Association between inflammation and changes in residual renal function and peritoneal transport rate during the first year of dialysis. Nephrol Dial Transplant. 2001; 16: 2240-2245.
22. Kolesnyk I, Noordzij M, Dekker FW, Boeschoten EW, Krediet RT. A positive effect of AII inhibitors on peritoneal membrane function in long-term PD patients. Nephrol Dial Transplant. 2009; 24: 272-277.
23. Jing S, Kezhou Y, Hong Z, Qun W, Rong W. Effect of renin-angiotensin system inhibitors on prevention of peritoneal fibrosis in peritoneal dialysis patients. Nephrology (Carlton). 2010; 15: 27-32.
24. Noh H, Ha H, Yu MR, Kim YO, Kim JH, Lee HB. Angiotensin II mediates high glucose-induced TGF-beta1 and fibronectin upregulation in HPMC through reactive oxygen species. Perit Dial Int. 2005; 25: 38-47.
25. Kiribayashi K, Masaki T, Naito T, Ogawa T, Ito T, Yorioka N, Kohno N. Angiotensin II induces fibronectin expression in human peritoneal mesothelial cells via ERK1/2 and p38 MAPK. Kidney Int. 2005; 67: 1126-1135.
26. Schröppel B, Fischereder M, Wiese P, Segerer S, Huber S, Kretzler M, Heiss P, Sitter T, Schlöndorff D. Expression of glucose transporters in human peritoneal mesothelial cells. Kidney Int. 1998; 53: 1 2 7 8 - 1 2 8 7.
27. Ha H, Cha MK, Choi HN, Lee HB. Effects of peritoneal dialysis solutions on the secretion of growth factors and extracellular matrix proteins by human peritoneal mesothelial cells. Perit Dial Int. 2002; 22: 171-177. PubMed.
28. Gilbert RE, Krum H, Wilkinson-Berka J, Kelly DJ. The renin-angiotensin system and the longterm complications of diabetes: pathophysiological and therapeutic considerations. Diabet Med. 2003; 20: 607-621.
29. Nakamoto H, Imai H, Fukushima R, Ishida Y, Yamanouchi Y, Suzuki H. Role of the renin-angiotensin system in the pathogenesis of peritoneal fibrosis. Perit Dial Int. 2008; 28 (Suppl 3): S83-S87. PubMed.
30. Margetts PJ, Kolb M, Galt T, Hoff CM, Shockley TR, Gauldie J. Gene transfer of transforming growth factor-beta1 to the rat peritoneum: effects on membrane function. J Am Soc Nephrol. 2001; 12: 2029-2039. PubMed.
31. Margetts PJ, Gyorffy S, Kolb M, Yu L, Hoff CM, Holmes CJ, Gauldie J. Antiangiogenic and antifibrotic gene therapy in a chronic infusion model of peritoneal dialysis in rats. J Am Soc Nephrol. 2002; 13: 721-728. PubMed.
32. Yáñez-Mó M, Lara-Pezzi E, Selgas R, Ramírez-Huesca M, Domínguez-Jiménez C, Jiménez-Heffernan JA, Aguilera A, Sánchez-Tomero JA, Bajo MA, Alvarez V, Castro MA, del Peso G, Cirujeda A, Gamallo C, Sánchez-Madrid F, López-Cabrera M. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med. 2003; 348: 403-413.
33. Deb DK, Sun T, Wong KE, Zhang Z, Ning G, Zhang Y, Kong J, Shi H, Chang A, Li YC. Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. Kidney Int. 2010; 77: 1000-1009.
34. Li YC; Yan Chun Li. Renoprotective effects of vitamin D analogs. Kidney Int. 2010; 78: 134-139.
35. Szeto CC, Chow KM, Kwan BC, Chung KY, Leung CB, Li PK. Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial. Am J Kidney Dis. 2008; 51: 724-731.
36. Coronel F, Rodríguez-Cubillo B, Cigarrán S, Gomis A. Effects of oral paricalcitol on hyperparathyroidism and proteinuria in peritoneal dialysis patients. Adv Perit Dial. 2011; 27: 130-133.
37. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003; 349: 446-456.
38. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernán MA, Camargo CA Jr, Thadhani R. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol. 2005; 16: 1115-1125.
39. Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Am J Nephrol. 2008; 28: 97-106.
40. Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int. 2006; 69: 33-43.